445-15412-01433
2 vaccinations
3 coded responses
25 check-ins
3 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 625 / IL
- Registered
- 2020-12-16
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-16
Registered in v-safe
-
2020-12-17
Dose 1 — Pfizer-BioNTech
- 2020-12-17
-
2020-12-18
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2020-12-19
- 2020-12-20
- 2020-12-21
- 2020-12-22
- 2020-12-23
- 2020-12-24
- 2020-12-31
- 2021-01-07
-
2021-01-08
Dose 2 — Pfizer-BioNTech
- 2021-01-09
- 2021-01-10
- 2021-01-11
- 2021-01-12
- 2021-01-13
- 2021-01-14
- 2021-01-15
- 2021-01-22
- 2021-01-29
- 2021-02-05
- 2021-02-12
- 2021-02-19
-
2021-04-09
Survey response — 3 months, dose 2MedDRA: Gestational hypertension — Feeling: Good · Be unable to work, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visit, HospitalizationFree text: Gestational hypertensionMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-04-09
Report sent to call center — 3 months, dose 2Be unable to work · Get care from a doctor or other healthcare professional1 call case(s)
- 2021-05-27
-
2021-07-09
Survey response — 6 months, dose 2MedDRA: Caesarean section, Pre-eclampsia — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · HospitalizationFree text: Preeclampsia, c sectionMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-07-09
Report sent to call center — 6 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare pr1 call case(s)
- 2021-07-14
-
2022-01-08
Survey response — 12 months, dose 2MedDRA: COVID-19 — Feeling: Good · Be unable to work or attend schoolFree text: CovidMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-17 | Pfizer-BioNTech | |
| 2 | 2021-01-08 | Pfizer-BioNTech |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-04-09 | Unsuccessful | |
| 2021-07-09 | Unsuccessful |
Free text
Release 7 — 3 months, dose 2
Symptoms: Gestational hypertension
Release 9 — 6 months, dose 2
Symptoms: Preeclampsia, c section
Release 10 — 12 months, dose 2
Symptoms: Covid
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Caesarean section | ✓ | ✓ | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Gestational hypertension | ✓ | ✓ | ✓ |
| SD | Pre-eclampsia | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release